Cathy Tie Pushes Embryo Gene Editing for Single-Gene Diseases at Origin Genomics
Updated
Updated · The Guardian · May 30
Cathy Tie Pushes Embryo Gene Editing for Single-Gene Diseases at Origin Genomics
3 articles · Updated · The Guardian · May 30
Origin Genomics is developing embryo gene-editing aimed at severe single-gene disorders, with Cathy Tie saying the startup wants to prove the approach is safe enough for eventual clinical use.
14 days is the legal limit for the embryos it now studies in the US; Tie says the company sequences cells before and after edits and will not implant embryos while seeking to persuade regulators and the public.
2018 remains the field’s defining warning: Tie’s former husband He Jiankui created the first gene-edited babies, was later jailed and fined 3 million yuan after unintended edits and a global backlash.
2025 has also brought fresh investor interest in rivals such as Preventive, backed by figures including Sam Altman and Brian Armstrong, underscoring growing commercial pressure around reproductive genetics.
Tie argues germline editing is inevitable and should start with disease prevention, but critics say safer alternatives already exist and warn the work could normalize enhancement and deepen inequality.
As the FDA opens the door to gene editing, is a global race for the first state-sanctioned 'perfect baby' now inevitable?
With a history of 'biohacked unicorns' and secret investors, can Biotech Barbie's gene-editing mission be trusted?
Origin Genomics and the 2026 Landscape of Embryo Gene Editing: Scientific Promise, Legal Barriers, and Societal Debate
Overview
Origin Genomics, led by Cathy Tie, is at the forefront of genetic research, focusing on foundational genomics while navigating strict U.S. and international regulations. The company is committed to responsible innovation, ensuring all activities stay within legal and ethical boundaries. Their leadership emphasizes transparency and caution, especially in research with potential clinical implications for human embryos. Despite exploring advanced gene editing technologies, Origin Genomics prioritizes ethical considerations and regulatory compliance, reflecting a strategic approach that balances scientific progress with societal expectations and current legal limitations.